Rapid effector function of varicella-zoster virus glycoprotein I-specific CD4+ T cells many decades after primary infection

Journal of Infectious Diseases

Volumn 195, Issue 5, 2007, Pages 660-664

  Malavige, Gathsaurie Neelika ^a,c   Jones, Louise ^a   Black, Antony Paul ^a   Ogg, Graham Stuart ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SRI JAYEWARDENEPURA   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN I; HLA DR ANTIGEN; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; EFFECTOR CELL; HERPES ZOSTER; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS IMMUNITY; VIRUS REPLICATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHICKENPOX; HERPESVIRUS 3, HUMAN; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; VIRAL ENVELOPE PROTEINS;

EID: 33847055116     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/511274     Document Type: Article

References (24)

1. Arvin AM. Immune responses to varicella-zoster virus. Infect Dis Clin North Am 1996; 10:529-70.
2. Patel PA, Yoonessi S, O'Malley J, Freeman A, Gershon A, Ogra PL. Cell-mediated immunity to varicella-zoster virus infection in subjects with lymphoma or leukemia. J Pediatr 1979; 94:223-30.
3. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 1986; 154:422-9.
4. Gershon AA, Steinberg SP. Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections. Infect Immun 1979; 25:170-4.
5. Diaz PS, Smith S, Hunter E, Arvin AM. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 1989; 142:636-41.
6. Sharp M, Terada K, Wilson A, et al. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis 1992; 165:852-8.
7. Watson B, Keller PM, Ellis RW, Starr SE. Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. J Infect Dis 1990; 162:794-9.
8. Park HB, Kim KC, Park JH, et al. Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol 2004; 31:2151-5.
9. Saibara T, Maeda T, Onishi S, Yamamoto Y. Depressed immune functions in the early phase of varicella-zoster virus reactivation. J Med Virol 1993; 39:242-5.
10. Sadzot-Delvaux C, Kinchington PR, Debrus S, Rentier B, Arvin AM. Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. J Immunol 1997; 159:2802-6.
11. Arvin AM, Sharp M, Smith S, et al. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol 1991; 146:257-64.
12. Bergen RE, Sharp M, Sanchez A, Judd AK, Arvin AM. Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Viral Immunol 1991;4:151-66.
13. Arvin AM, Sharp M, Moir M, et al. Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus. Viral Immunol 2002; 15:507-16.
14. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 2000; 181:859-66.
15. Khan N, Hislop A, Gudgeon N, et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a co-resident EBV infection. J Immunol 2004; 173:7481-9.
16. + T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 2003; 188:40-52.
17. Moffat J, Ito H, Sommer M, Taylor S, Arvin AM. Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J Virol 2002; 76:8468-71.
18. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a γ-interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001; 8:871-9.
19. Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169:3447-58.
20. Banerjee G, Damodaran A, Devi N, Dharmalingam K, Raman G. Role of keratinocytes in antigen presentation and polarization of human T lymphocytes. Scand J Immunol 2004; 59:385-94.
21. Morizane S, Suzuki D, Tsuji K, Oono T, Iwatsuki K. The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles. Br J Dermatol 2005; 153:981-6.
22. Bellner L, Lowhagen GB, Tunback P, Nordstrom I, Liljeqvist JA, Eriksson K. Characterization of T-cell reactive epitopes in glycoprotein G of herpes simplex virus type 2 using synthetic peptides. Arch Virol 2005; 150:1393-406.
23. Hegde NR, Dunn C, Lewinsohn DM, Jarvis MA, Nelson JA, Johnson DC. Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. J Exp Med 2005; 202:1109-19.
24. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol 2001;75:4878-88.